XCeed appoints manufacturer
11 June, 2004 by Renate KrelleRecently-listed XCeed Biotechnology (ASX:XBL) has announced that its subsidiary Polymerco will use Melbourne-based AorTech to manufacture its biodegradeable polyurethane. The product has applications in orthapaedics, wound repair, drug delivery and stents.
BIO 2004: Big-spending Beattie bids more on biotech
10 June, 2004 by Melissa TrudingerQueensland premier Peter Beattie has used the BIO 2004 conference in San Francisco as a platform to announce more than AUD$45 million of funding for clinical and medical research, clinical trials, smart foods and research facilities in the state.
Panbio, La Trobe win malaria diagnostic grant
10 June, 2004 by Graeme O'NeillBrisbane diagnostics company Panbio (ASX:PBO) and La Trobe University have received a $117,000 development grant from the National Health and Medical Research Council to develop a simple, rapid, point-of-care diagnostic for malaria.
Biota steps up Glaxo lawsuit
10 June, 2004 by Renate KrelleBiota Holdings (ASX:BTA) has filed a statement of claim in the Victorian Supreme Court, moving its litigation against GlaxoSmithKline forward a step.
AGT merger partner's cancer drug results promising
10 June, 2004 by Melissa TrudingerClinical results from AGT Bioscience's merger partner ChemGenex Therapeutics' Phase I/II trial of cancer drug Quinamed, released yesterday at ASCO in New Orleans and BIO in San Francisco, have shown promising anti-cancer activity, the company has claimed.
LCT diabetes technology makes debut in Italian trial
09 June, 2004 by Graeme O'NeillItalian researchers have transplanted insulin-secreting pancreatic islet cells into a 37-year old man with type 1 diabetes, in the first of a 10-patient pilot trial of a potentially revolutionary treatment for diabetes developed by Australian biomedical company Living Cell Technologies (NSX:LCT).
Chemeq raises $10m
09 June, 2004 by Graeme O'NeillPerth pharmaceutical company Chemeq (ASX:CMQ) has raised AUD$10 million from a share placement to institutional and private clients with Bell Potter Securities.
ASCO: Celgene says blood cancer patients respond to Thalidomide
08 June, 2004 by Staff WritersThalidomide, a cause of severe birth defects in children in the 1950's, and currently approved for the treatment of leprosy, was found to be effective in a clinical trial for treating patients with multiple myeloma, a form of blood cancer.
Panbio nets grant, moves most manufacturing to Brisbane
08 June, 2004 by Graeme O'NeillMedical diagnostics company Panbio (ASX:PBO) has been awarded a Queensland government grant towards the cost of developing its new R&D and manufacturing facility in Brisbane.
Ambri system makes clinical debut
07 June, 2004 by Renate KrelleThe first diagnostic system to use an ion-channel switch, able to sense tiny concentrations of a specific molecule, has been installed in the pathology laboratory at Sydney's Royal North Shore Hospital.
Austin, Ludwig to run PII melanoma vaccine trial
07 June, 2004 by Melissa TrudingerThe Austin Health/Ludwig Institute of Cancer Research (LICR) joint oncology unit has received a grant of US$600,000 from US-based cancer charity, the Cancer Research Institute (CRI), to conduct an international Phase II clinical trial that will test the effectiveness of a therapeutic vaccine for melanoma.
EQiTX pain-soothing molecules show promise
04 June, 2004 by Graeme O'NeillResearch by a University of Queensland research team suggests Melbourne-based biotech ZingoTX may have a lead compound for neuropathic pain in its synthetic derivatives of the mouth-burning molecules found in ginger and chillies.
Bayer pulls plug on GM canola trial in NSW
04 June, 2004 by Graeme O'NeillAt the last minute, Agbiotech giant Bayer CropScience has pulled the plug on its plan to conduct a 40-hectare demonstration trial of its genetically modified hybrid canolas in NSW.
GTG to DNA-test 20,000 NZ sheep
04 June, 2004 by Graeme O'NeillMelbourne biotech Genetic Technologies (ASX:GTG) has signed its first contract with New Zealand agbiotech company Ovita in Dunedin for a pilot program to DNA-test up to 20,000 sheep.
Amrad stunned as Serono drops emfilermin trial
04 June, 2004 by Melissa TrudingerAmrad (ASX:AML) has been dealt a blow with the news that Serono is abandoning further development of emfilermin following Phase II clinical trial results that showed the molecule was no more efficacious than the placebo.
